Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.58 -0.8%	$2.16	$1.20 ▼ $6.75	$146.71M	2.71	1.56 million shs	472,335 shs
BEAM Beam Therapeutics	$20.02 +0.7%	$17.64	$13.53 ▼ $35.25	$2.01B	2.07	1.51 million shs	1.36 million shs
NSTG NanoString Technologies		$0.36	$0.05 ▼ $11.78	$5.07M	1.24	34.54 million shs	23.06 million shs
ORTX Orchard Therapeutics	$16.70	$16.59	$4.24 ▼ $16.72	$380.09M	0.55	157,287 shs	N/A
TWST Twist Bioscience	$38.11 +1.1%	$33.49	$27.12 ▼ $60.90	$2.29B	2.41	966,972 shs	445,333 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	0.00%	+9.79%	+3.61%	+84.29%	-41.89%
BEAM Beam Therapeutics	0.00%	+19.17%	+17.76%	+31.11%	-14.74%
NSTG NanoString Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
ORTX Orchard Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TWST Twist Bioscience	0.00%	+6.07%	+25.65%	+5.31%	-20.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.1219 of 5 stars	3.5	3.0	0.0	0.0	3.6	1.7	0.6
BEAM Beam Therapeutics	2.4834 of 5 stars	3.5	1.0	0.0	0.0	2.5	2.5	0.6
NSTG NanoString Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORTX Orchard Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	4.462 of 5 stars	4.4	2.0	0.0	4.4	2.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.00	Buy	$12.80	396.12% Upside
BEAM Beam Therapeutics	3.00	Buy	$48.75	143.51% Upside
NSTG NanoString Technologies	0.00	N/A	N/A	N/A
ORTX Orchard Therapeutics	0.00	N/A	N/A	N/A
TWST Twist Bioscience	2.70	Moderate Buy	$50.40	32.25% Upside

Current Analyst Ratings Breakdown

Latest NSTG, TWST, ORTX, BDTX, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$11.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
5/6/2025	TWST Twist Bioscience	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
5/6/2025	TWST Twist Bioscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
5/6/2025	TWST Twist Bioscience	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $44.00
5/6/2025	TWST Twist Bioscience	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
4/10/2025	TWST Twist Bioscience	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$58.00 ➝ $45.00
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	$1.47 per share	N/A
BEAM Beam Therapeutics	$63.52M	31.69	N/A	N/A	$8.86 per share	2.26
NSTG NanoString Technologies	$127.26M	0.00	N/A	N/A	$0.98 per share	0.00
ORTX Orchard Therapeutics	$22.66M	16.77	N/A	N/A	$7.74 per share	2.16
TWST Twist Bioscience	$312.97M	7.30	N/A	N/A	$8.07 per share	4.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$69.68M	$0.06	43.00	N/A	N/A	N/A	4.70%	3.47%	8/5/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
NSTG NanoString Technologies	-$159.54M	-$3.53	N/A	N/A	N/A	-102.44%	-548.25%	-53.79%	N/A
ORTX Orchard Therapeutics	-$150.66M	-$0.94	N/A	N/A	N/A	-333.90%	-74.94%	-33.51%	N/A
TWST Twist Bioscience	-$208.73M	-$3.25	N/A	N/A	N/A	-54.98%	-33.48%	-25.34%	8/1/2025 (Estimated)

Latest NSTG, TWST, ORTX, BDTX, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q3 2025	TWST Twist Bioscience	-$0.54	N/A	N/A	N/A	$95.52 million	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/5/2025	Q2 2025	TWST Twist Bioscience	-$0.56	-$0.66	-$0.10	-$0.66	$92.00 million	$92.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
NSTG NanoString Technologies	N/A	N/A	N/A	N/A	N/A
ORTX Orchard Therapeutics	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	9.24	9.24
BEAM Beam Therapeutics	N/A	8.81	8.81
NSTG NanoString Technologies	N/A	2.73	2.02
ORTX Orchard Therapeutics	0.20	3.12	2.98
TWST Twist Bioscience	0.03	4.51	4.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
BEAM Beam Therapeutics	99.68%
NSTG NanoString Technologies	N/A
ORTX Orchard Therapeutics	29.90%
TWST Twist Bioscience	N/A

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	5.97%
BEAM Beam Therapeutics	3.50%
NSTG NanoString Technologies	3.10%
ORTX Orchard Therapeutics	2.91%
TWST Twist Bioscience	3.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.86 million	53.47 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
NSTG NanoString Technologies	550	48.12 million	46.63 million	Optionable
ORTX Orchard Therapeutics	166	22.76 million	22.10 million	Optionable
TWST Twist Bioscience	990	59.92 million	58.11 million	Optionable

NSTG, TWST, ORTX, BDTX, and BEAM Headlines

Recent News About These Companies

Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 2, 2025 | americanbankingnews.com

Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Rating of "Moderate Buy" by Brokerages

July 2, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Shares Sold by Sumitomo Mitsui Trust Group Inc.

June 30, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) SVP Sells $10,441.92 in Stock

June 25, 2025 | insidertrades.com

Insider Selling: Twist Bioscience Corporation (NASDAQ:TWST) SVP Sells 292 Shares of Stock

June 24, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily M. Leproust Sells 1,678 Shares

June 24, 2025 | marketbeat.com

Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions

June 23, 2025 | insidermonkey.com

SG Americas Securities LLC Acquires New Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

June 19, 2025 | marketbeat.com

Twist Bioscience (NASDAQ:TWST) Trading 7.2% Higher - Time to Buy?

June 18, 2025 | marketbeat.com

Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation

June 16, 2025 | finance.yahoo.com

Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by GAMMA Investing LLC

June 16, 2025 | marketbeat.com

NBC Securities Inc. Takes $337,000 Position in Twist Bioscience Co. (NASDAQ:TWST)

June 7, 2025 | marketbeat.com

Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Rating of "Moderate Buy" by Analysts

June 7, 2025 | marketbeat.com

Twist Bioscience (NASDAQ:TWST) Shares Gap Up - Here's What Happened

June 6, 2025 | marketbeat.com

Twist Bioscience Co. (NASDAQ:TWST) CAO Robert F. Werner Sells 839 Shares

May 29, 2025 | insidertrades.com

Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 531 Shares

May 24, 2025 | insidertrades.com

Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference

May 15, 2025 | 01net.it0

Twist Bioscience Corporation (TWST): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential

May 9, 2025 | msn.com

Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 689 Shares

May 8, 2025 | insidertrades.com

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

May 8, 2025 | businesswire.com

TWIST BIOSCIENCE Earnings Results: $TWST Reports Quarterly Earnings

May 7, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NSTG, TWST, ORTX, BDTX, and BEAM Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.58 -0.02 (-0.77%)

Closing price 07/3/2025 03:42 PM Eastern

Extended Trading

$2.59 +0.01 (+0.39%)

As of 07/3/2025 04:58 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Beam Therapeutics NASDAQ:BEAM

$20.02 +0.14 (+0.70%)

Closing price 07/3/2025 03:12 PM Eastern

Extended Trading

$20.19 +0.17 (+0.84%)

As of 07/3/2025 04:55 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

NanoString Technologies NASDAQ:NSTG

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Orchard Therapeutics NASDAQ:ORTX

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

Twist Bioscience NASDAQ:TWST

$38.11 +0.43 (+1.14%)

Closing price 07/3/2025 03:40 PM Eastern

Extended Trading

$38.52 +0.41 (+1.09%)

As of 07/3/2025 04:20 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time